Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
|
MILLENNIUM PHARMACEUTICALS INC (MLNM)
|
Add to portfolio |
|
|
|
| Price: |
$24.97
| | Metrics |
| OS: |
321.1
|
M
| |
|
|
| Market cap: |
$8.02
|
B
| |
|
|
|
Net cash:
|
$607
|
M
| |
$1.89
|
per share
|
|
EV:
|
$7.41
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$73.2
|
M
| |
101.2
|
x EV/EBITDA
|
|
EBIT
|
$2.5
|
M
| |
2943.5
|
x EV/EBIT
|
| EPS |
$76.02
| |
0.3
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 |
| Revenues | 527.5 | 486.8 | 558.3 | 448.2 | 433.7 | 353.0 | 246.2 | 196.3 |
| Revenue growth | 8.4% | -12.8% | 24.6% | 3.3% | 22.8% | 43.4% | 25.4% | 22.8% |
| Cost of goods sold | 28.4 | 45.4 | 141.3 | 70.3 | 61.2 | 47.3 | 0.0 | 268.7 |
| Gross profit | 499.1 | 441.4 | 417.0 | 377.9 | 372.5 | 305.8 | 246.2 | -72.5 |
| Gross margin | 94.6% | 90.7% | 74.7% | 84.3% | 85.9% | 86.6% | 100.0% | -36.9% |
| Selling, general and administrative | 189.1 | 162.9 | 188.7 | 196.6 | 178.8 | 168.9 | 82.7 | 49.3 |
| Research and development | 287.1 | 310.9 | 334.1 | 402.6 | 488.5 | 511.2 | 400.6 | |
| EBITA | 23.0 | -32.4 | -105.8 | -221.3 | -294.9 | -374.3 | -237.0 | -121.8 |
| EBITA margin | 4.4% | -6.7% | -19.0% | -49.4% | -68.0% | -106.0% | -96.3% | -62.1% |
| Amortization of intangibles | 34.0 | 34.0 | 34.0 | 33.5 | 38.9 | 34.9 | 64.6 | 55.1 |
| EBIT | -11.0 | -66.4 | -139.8 | -254.8 | -333.8 | -409.3 | -301.6 | -176.9 |
| EBIT margin | -2.1% | -13.6% | -25.0% | -56.8% | -77.0% | -115.9% | -122.5% | -90.1% |
| Pre-tax income | 0.0 | 0.0 | 0.0 | -252.3 | -483.7 | -590.2 | -192.0 | -309.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 0.0 | 0.0 | 0.0 | -252.3 | -483.7 | -590.2 | -192.0 | -0.4 |
| Net margin | 0.0% | 0.0% | 0.0% | -56.3% | -111.5% | -167.2% | -78.0% | -0.2% |
| |
| Diluted EPS | $0.00 | $0.00 | $0.00 | ($0.83) | ($1.63) | ($2.13) | ($876.99) | ($1.84) |
| Shares outstanding (diluted) | 0.3 | 0.3 | 0.3 | 304.8 | 297.6 | 277.7 | 0.2 | 0.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|